58349-01-2

Basic information

• Product Name: 4-BROMO-2-CHLORO-6-NITROPHENOL
• Synonyms: 4-BROMO-2-CHLORO-6-NITROPHENOL
• CAS NO: 58349-01-2
• Molecular Formula: C₆H₃BrClNO₃
• Molecular Weight: 252.45
• Mol File: 58349-01-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 257 °C at 760 mmHg
• Flash Point: 109.2 °C
• Appearance: /
• Density: 1.974 g/cm³
• Vapor Pressure: 0.00929mmHg at 25°C
• Refractive Index: 1.661
• CAS DataBase Reference: 4-BROMO-2-CHLORO-6-NITROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-CHLORO-6-NITROPHENOL(58349-01-2)
• EPA Substance Registry System: 4-BROMO-2-CHLORO-6-NITROPHENOL(58349-01-2)

Safety Data

• Hazardous Substances Data: 58349-01-2(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-chloro-6-nitrophenol is a chemical compound that belongs to the class of phenols and is characterized by the presence of a bromine, chlorine, and nitro group on a phenol ring. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, as well as in the preparation of dyes and pigments. 4-BROMO-2-CHLORO-6-NITROPHENOL has been found to have potential anti-bacterial and anti-fungal properties, making it useful in the development of pharmaceuticals for the treatment of microbial infections. Additionally, it is also used in the production of insecticides and herbicides. 4-Bromo-2-chloro-6-nitrophenol is a yellow crystalline solid with a melting point of 92-95°C, and is considered to be a hazardous chemical that requires careful handling and storage due to its toxic and irritant properties.

InChI:InChI=1/C6H3BrClNO3/c7-3-1-4(8)6(10)5(2-3)9(11)12/h1-2,10H

Upstream product

• 7693-52-9 4-bromo-2-nitrophenol 
• 3964-56-5 4-bromo-2-chlorophenol 
• 4526-56-1 2,4-dibromo-6-chlorophenol 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 603-86-1 2-chloro-6-nitrophenol 
• 95-57-8 2-monochlorophenol 
• 50638-47-6 4-bromo-2-chloro-1-methoxybenzene 

Downstream Products

• 46008-81-5 tribromo-chloro-[1,4]benzoquinone 
• 946-31-6 2-chloro-4,6-dinitro-phenol 
• 20294-55-7 2-bromo-6-chloro-4-nitrophenol 
• 26361-21-7 2-bromo-5-chloro-3,6-dihydroxy-[1,4]benzoquinone 
• 85531-44-8 2,3,5-tribromo-6-chloro-hydroquinone 
• 943994-32-9 methyl 2-(4-bromo-2-chloro-6-nitrophenoxy)acetate 
• 121564-96-3 6-bromo-8-chloro-2H-1,4-benzoxazin-3(4H)-one 
• 1426321-16-5 N-(5-bromo-3-chloro-2-hydroxyphenyl)cyclopropanecarboxamide 
• 1438262-45-3 4-bromo-2-chloro-6-cyclopropaneamidophenyl cyclopropanecarboxylate 
• 1226018-90-1 C₁₀H₇BrClNO 

Relevant articles and documents

CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS

The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical comopositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disesase) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and diso